nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—Parathyroid disorder—Riluzole—amyotrophic lateral sclerosis	0.0313	0.0555	CcSEcCtD
Sirolimus—MTOR—forelimb—amyotrophic lateral sclerosis	0.0197	0.117	CbGeAlD
Sirolimus—MTOR—hindlimb—amyotrophic lateral sclerosis	0.0177	0.105	CbGeAlD
Sirolimus—MTOR—appendage—amyotrophic lateral sclerosis	0.0152	0.09	CbGeAlD
Sirolimus—Peritonitis—Riluzole—amyotrophic lateral sclerosis	0.0143	0.0253	CcSEcCtD
Sirolimus—EIF4E—embryo—amyotrophic lateral sclerosis	0.013	0.0773	CbGeAlD
Sirolimus—Circumoral paresthesia—Riluzole—amyotrophic lateral sclerosis	0.0111	0.0196	CcSEcCtD
Sirolimus—Tetany—Riluzole—amyotrophic lateral sclerosis	0.0111	0.0196	CcSEcCtD
Sirolimus—Osteonecrosis—Riluzole—amyotrophic lateral sclerosis	0.00967	0.0172	CcSEcCtD
Sirolimus—Pyelonephritis—Riluzole—amyotrophic lateral sclerosis	0.00948	0.0168	CcSEcCtD
Sirolimus—Fungal skin infection—Riluzole—amyotrophic lateral sclerosis	0.00863	0.0153	CcSEcCtD
Sirolimus—MTOR—hindbrain—amyotrophic lateral sclerosis	0.00807	0.0478	CbGeAlD
Sirolimus—Hernia—Riluzole—amyotrophic lateral sclerosis	0.00768	0.0137	CcSEcCtD
Sirolimus—Paraesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.00768	0.0137	CcSEcCtD
Sirolimus—Thrombocytopenic purpura—Riluzole—amyotrophic lateral sclerosis	0.00768	0.0137	CcSEcCtD
Sirolimus—Peripheral vascular disorder—Riluzole—amyotrophic lateral sclerosis	0.00735	0.0131	CcSEcCtD
Sirolimus—Pneumothorax—Riluzole—amyotrophic lateral sclerosis	0.00724	0.0129	CcSEcCtD
Sirolimus—Muscle relaxant therapy—Riluzole—amyotrophic lateral sclerosis	0.00724	0.0129	CcSEcCtD
Sirolimus—Hypotonia—Riluzole—amyotrophic lateral sclerosis	0.00685	0.0122	CcSEcCtD
Sirolimus—Renal pain—Riluzole—amyotrophic lateral sclerosis	0.00685	0.0122	CcSEcCtD
Sirolimus—Urine abnormality—Riluzole—amyotrophic lateral sclerosis	0.00651	0.0116	CcSEcCtD
Sirolimus—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.00643	0.0114	CcSEcCtD
Sirolimus—EIF4E—nervous system—amyotrophic lateral sclerosis	0.00626	0.0371	CbGeAlD
Sirolimus—SLC47A1—hindbrain—amyotrophic lateral sclerosis	0.00624	0.037	CbGeAlD
Sirolimus—Urine analysis abnormal—Riluzole—amyotrophic lateral sclerosis	0.00613	0.0109	CcSEcCtD
Sirolimus—Generalised oedema—Riluzole—amyotrophic lateral sclerosis	0.00606	0.0108	CcSEcCtD
Sirolimus—EIF4E—central nervous system—amyotrophic lateral sclerosis	0.00603	0.0357	CbGeAlD
Sirolimus—Enlargement abdomen—Riluzole—amyotrophic lateral sclerosis	0.00599	0.0106	CcSEcCtD
Sirolimus—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00592	0.0105	CcSEcCtD
Sirolimus—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00567	0.0101	CcSEcCtD
Sirolimus—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00539	0.00958	CcSEcCtD
Sirolimus—Blood creatine phosphokinase increased—Riluzole—amyotrophic lateral sclerosis	0.00524	0.0093	CcSEcCtD
Sirolimus—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00519	0.00922	CcSEcCtD
Sirolimus—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00509	0.00905	CcSEcCtD
Sirolimus—Ileus—Riluzole—amyotrophic lateral sclerosis	0.00509	0.00905	CcSEcCtD
Sirolimus—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00509	0.00905	CcSEcCtD
Sirolimus—FGF2—medulla oblongata—amyotrophic lateral sclerosis	0.00508	0.0301	CbGeAlD
Sirolimus—MTOR—embryo—amyotrophic lateral sclerosis	0.00505	0.0299	CbGeAlD
Sirolimus—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00504	0.00896	CcSEcCtD
Sirolimus—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.00487	0.00865	CcSEcCtD
Sirolimus—EIF4E—brain—amyotrophic lateral sclerosis	0.00479	0.0284	CbGeAlD
Sirolimus—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00471	0.00836	CcSEcCtD
Sirolimus—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00463	0.00822	CcSEcCtD
Sirolimus—MTOR—brainstem—amyotrophic lateral sclerosis	0.00462	0.0274	CbGeAlD
Sirolimus—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00455	0.00809	CcSEcCtD
Sirolimus—FGF2—spinal cord—amyotrophic lateral sclerosis	0.00453	0.0268	CbGeAlD
Sirolimus—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.00445	0.0079	CcSEcCtD
Sirolimus—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.00428	0.00761	CcSEcCtD
Sirolimus—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.0041	0.00729	CcSEcCtD
Sirolimus—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.00407	0.00724	CcSEcCtD
Sirolimus—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00399	0.00709	CcSEcCtD
Sirolimus—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00396	0.00704	CcSEcCtD
Sirolimus—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00396	0.00704	CcSEcCtD
Sirolimus—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00394	0.00699	CcSEcCtD
Sirolimus—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00388	0.0069	CcSEcCtD
Sirolimus—Gout—Riluzole—amyotrophic lateral sclerosis	0.00386	0.00686	CcSEcCtD
Sirolimus—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00383	0.00681	CcSEcCtD
Sirolimus—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00381	0.00677	CcSEcCtD
Sirolimus—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00379	0.00673	CcSEcCtD
Sirolimus—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.0036	0.0064	CcSEcCtD
Sirolimus—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.0036	0.0064	CcSEcCtD
Sirolimus—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.0036	0.0064	CcSEcCtD
Sirolimus—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.0036	0.0064	CcSEcCtD
Sirolimus—FGF2—cerebellum—amyotrophic lateral sclerosis	0.00359	0.0213	CbGeAlD
Sirolimus—SLC47A1—brainstem—amyotrophic lateral sclerosis	0.00357	0.0212	CbGeAlD
Sirolimus—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00348	0.00618	CcSEcCtD
Sirolimus—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00344	0.00611	CcSEcCtD
Sirolimus—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00342	0.00608	CcSEcCtD
Sirolimus—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00331	0.00588	CcSEcCtD
Sirolimus—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00326	0.00579	CcSEcCtD
Sirolimus—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00326	0.00579	CcSEcCtD
Sirolimus—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00321	0.0057	CcSEcCtD
Sirolimus—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00316	0.00561	CcSEcCtD
Sirolimus—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00313	0.00556	CcSEcCtD
Sirolimus—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00307	0.00545	CcSEcCtD
Sirolimus—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00307	0.00545	CcSEcCtD
Sirolimus—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00301	0.00534	CcSEcCtD
Sirolimus—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00301	0.00534	CcSEcCtD
Sirolimus—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00292	0.0052	CcSEcCtD
Sirolimus—FGF2—brain—amyotrophic lateral sclerosis	0.00292	0.0173	CbGeAlD
Sirolimus—FKBP1A—medulla oblongata—amyotrophic lateral sclerosis	0.0029	0.0172	CbGeAlD
Sirolimus—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00288	0.00512	CcSEcCtD
Sirolimus—MTOR—spinal cord—amyotrophic lateral sclerosis	0.00288	0.017	CbGeAlD
Sirolimus—Injury—Riluzole—amyotrophic lateral sclerosis	0.00285	0.00506	CcSEcCtD
Sirolimus—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00495	CcSEcCtD
Sirolimus—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00277	0.00493	CcSEcCtD
Sirolimus—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00276	0.0049	CcSEcCtD
Sirolimus—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.0027	0.0048	CcSEcCtD
Sirolimus—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00467	CcSEcCtD
Sirolimus—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00262	0.00465	CcSEcCtD
Sirolimus—FKBP1A—spinal cord—amyotrophic lateral sclerosis	0.00259	0.0153	CbGeAlD
Sirolimus—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00257	0.00457	CcSEcCtD
Sirolimus—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00449	CcSEcCtD
Sirolimus—SLC47A1—medulla oblongata—amyotrophic lateral sclerosis	0.00249	0.0148	CbGeAlD
Sirolimus—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00249	0.00442	CcSEcCtD
Sirolimus—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00248	0.0044	CcSEcCtD
Sirolimus—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00432	CcSEcCtD
Sirolimus—MTOR—nervous system—amyotrophic lateral sclerosis	0.00242	0.0144	CbGeAlD
Sirolimus—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00241	0.00429	CcSEcCtD
Sirolimus—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00239	0.00424	CcSEcCtD
Sirolimus—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00238	0.00423	CcSEcCtD
Sirolimus—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00236	0.0042	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00236	0.00419	CcSEcCtD
Sirolimus—MTOR—central nervous system—amyotrophic lateral sclerosis	0.00233	0.0138	CbGeAlD
Sirolimus—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00231	0.00411	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00231	0.0041	CcSEcCtD
Sirolimus—MTOR—cerebellum—amyotrophic lateral sclerosis	0.00228	0.0135	CbGeAlD
Sirolimus—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00404	CcSEcCtD
Sirolimus—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00402	CcSEcCtD
Sirolimus—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00402	CcSEcCtD
Sirolimus—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00402	CcSEcCtD
Sirolimus—SLC47A1—spinal cord—amyotrophic lateral sclerosis	0.00222	0.0132	CbGeAlD
Sirolimus—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00222	0.00394	CcSEcCtD
Sirolimus—FKBP1A—nervous system—amyotrophic lateral sclerosis	0.00218	0.0129	CbGeAlD
Sirolimus—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00217	0.00386	CcSEcCtD
Sirolimus—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00215	0.00381	CcSEcCtD
Sirolimus—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00376	CcSEcCtD
Sirolimus—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00376	CcSEcCtD
Sirolimus—FKBP1A—central nervous system—amyotrophic lateral sclerosis	0.0021	0.0124	CbGeAlD
Sirolimus—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00371	CcSEcCtD
Sirolimus—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00208	0.0037	CcSEcCtD
Sirolimus—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00366	CcSEcCtD
Sirolimus—FKBP1A—cerebellum—amyotrophic lateral sclerosis	0.00205	0.0121	CbGeAlD
Sirolimus—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00363	CcSEcCtD
Sirolimus—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00203	0.0036	CcSEcCtD
Sirolimus—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00358	CcSEcCtD
Sirolimus—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00358	CcSEcCtD
Sirolimus—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00198	0.00351	CcSEcCtD
Sirolimus—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00196	0.00349	CcSEcCtD
Sirolimus—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00196	0.00348	CcSEcCtD
Sirolimus—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00343	CcSEcCtD
Sirolimus—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00341	CcSEcCtD
Sirolimus—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00339	CcSEcCtD
Sirolimus—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00338	CcSEcCtD
Sirolimus—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00336	CcSEcCtD
Sirolimus—SLC47A1—nervous system—amyotrophic lateral sclerosis	0.00187	0.0111	CbGeAlD
Sirolimus—MTOR—brain—amyotrophic lateral sclerosis	0.00185	0.011	CbGeAlD
Sirolimus—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00323	CcSEcCtD
Sirolimus—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00322	CcSEcCtD
Sirolimus—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00322	CcSEcCtD
Sirolimus—SLC47A1—central nervous system—amyotrophic lateral sclerosis	0.0018	0.0107	CbGeAlD
Sirolimus—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.0018	0.0032	CcSEcCtD
Sirolimus—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.0018	0.0032	CcSEcCtD
Sirolimus—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00319	CcSEcCtD
Sirolimus—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00318	CcSEcCtD
Sirolimus—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00317	CcSEcCtD
Sirolimus—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00316	CcSEcCtD
Sirolimus—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00315	CcSEcCtD
Sirolimus—SLC47A1—cerebellum—amyotrophic lateral sclerosis	0.00176	0.0104	CbGeAlD
Sirolimus—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00298	CcSEcCtD
Sirolimus—FKBP1A—brain—amyotrophic lateral sclerosis	0.00167	0.00987	CbGeAlD
Sirolimus—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00292	CcSEcCtD
Sirolimus—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00163	0.0029	CcSEcCtD
Sirolimus—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00163	0.0029	CcSEcCtD
Sirolimus—Chills—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00288	CcSEcCtD
Sirolimus—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00158	0.0028	CcSEcCtD
Sirolimus—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00276	CcSEcCtD
Sirolimus—Tension—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00275	CcSEcCtD
Sirolimus—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00272	CcSEcCtD
Sirolimus—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00271	CcSEcCtD
Sirolimus—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00269	CcSEcCtD
Sirolimus—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00262	CcSEcCtD
Sirolimus—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00146	0.0026	CcSEcCtD
Sirolimus—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00259	CcSEcCtD
Sirolimus—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00257	CcSEcCtD
Sirolimus—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00256	CcSEcCtD
Sirolimus—SLC47A1—brain—amyotrophic lateral sclerosis	0.00143	0.00848	CbGeAlD
Sirolimus—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00252	CcSEcCtD
Sirolimus—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00251	CcSEcCtD
Sirolimus—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00251	CcSEcCtD
Sirolimus—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00247	CcSEcCtD
Sirolimus—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00246	CcSEcCtD
Sirolimus—Cough—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00244	CcSEcCtD
Sirolimus—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00242	CcSEcCtD
Sirolimus—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00238	CcSEcCtD
Sirolimus—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00238	CcSEcCtD
Sirolimus—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00238	CcSEcCtD
Sirolimus—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00237	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00237	CcSEcCtD
Sirolimus—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00235	CcSEcCtD
Sirolimus—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.0013	0.0023	CcSEcCtD
Sirolimus—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00228	CcSEcCtD
Sirolimus—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00228	CcSEcCtD
Sirolimus—Infection—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00227	CcSEcCtD
Sirolimus—Shock—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00225	CcSEcCtD
Sirolimus—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00224	CcSEcCtD
Sirolimus—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00224	CcSEcCtD
Sirolimus—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00223	CcSEcCtD
Sirolimus—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00222	CcSEcCtD
Sirolimus—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00221	CcSEcCtD
Sirolimus—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00218	CcSEcCtD
Sirolimus—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00213	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00208	CcSEcCtD
Sirolimus—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00207	CcSEcCtD
Sirolimus—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00205	CcSEcCtD
Sirolimus—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00204	CcSEcCtD
Sirolimus—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00203	CcSEcCtD
Sirolimus—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00201	CcSEcCtD
Sirolimus—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00199	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00197	CcSEcCtD
Sirolimus—Constipation—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00195	CcSEcCtD
Sirolimus—Pain—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00195	CcSEcCtD
Sirolimus—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00188	CcSEcCtD
Sirolimus—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00187	CcSEcCtD
Sirolimus—ABCB1—embryo—amyotrophic lateral sclerosis	0.00105	0.00622	CbGeAlD
Sirolimus—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00181	CcSEcCtD
Sirolimus—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00181	CcSEcCtD
Sirolimus—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000947	0.00168	CcSEcCtD
Sirolimus—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000922	0.00164	CcSEcCtD
Sirolimus—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00091	0.00162	CcSEcCtD
Sirolimus—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00088	0.00156	CcSEcCtD
Sirolimus—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00085	0.00151	CcSEcCtD
Sirolimus—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000817	0.00145	CcSEcCtD
Sirolimus—Rash—Riluzole—amyotrophic lateral sclerosis	0.000811	0.00144	CcSEcCtD
Sirolimus—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00081	0.00144	CcSEcCtD
Sirolimus—Headache—Riluzole—amyotrophic lateral sclerosis	0.000805	0.00143	CcSEcCtD
Sirolimus—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000764	0.00136	CcSEcCtD
Sirolimus—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000712	0.00422	CbGeAlD
Sirolimus—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000686	0.00406	CbGeAlD
Sirolimus—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000671	0.00397	CbGeAlD
Sirolimus—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000598	0.00354	CbGeAlD
Sirolimus—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000504	0.00299	CbGeAlD
Sirolimus—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000485	0.00288	CbGeAlD
Sirolimus—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000474	0.00281	CbGeAlD
Sirolimus—ABCB1—brain—amyotrophic lateral sclerosis	0.000385	0.00228	CbGeAlD
Sirolimus—FGF2—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	0.000233	0.00087	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—GSTP1—amyotrophic lateral sclerosis	0.000231	0.00086	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000223	0.000832	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.000223	0.00083	CbGpPWpGaD
Sirolimus—FGF2—Disease—PLB1—amyotrophic lateral sclerosis	0.00022	0.000818	CbGpPWpGaD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000218	0.000814	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000217	0.000808	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000214	0.000798	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000214	0.000798	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000212	0.00079	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.000212	0.000789	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	0.000212	0.000788	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.00021	0.000781	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—ATF1—amyotrophic lateral sclerosis	0.000209	0.000779	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000209	0.000778	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000208	0.000776	CbGpPWpGaD
Sirolimus—MTOR—AMPK Signaling—TP53—amyotrophic lateral sclerosis	0.000208	0.000776	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000203	0.000756	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000202	0.000753	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.0002	0.000744	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.000199	0.000743	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CASP9—amyotrophic lateral sclerosis	0.000199	0.000742	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000197	0.000733	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000197	0.000733	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000196	0.00073	CbGpPWpGaD
Sirolimus—FGF2—Disease—VCP—amyotrophic lateral sclerosis	0.000196	0.000729	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—amyotrophic lateral sclerosis	0.000194	0.000723	CbGpPWpGaD
Sirolimus—FGF2—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000194	0.000723	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000194	0.000722	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000193	0.000718	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000191	0.000711	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.00019	0.000709	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.00019	0.000708	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.00019	0.000708	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.00019	0.000708	CbGpPWpGaD
Sirolimus—CYP3A5—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000186	0.000691	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CST3—amyotrophic lateral sclerosis	0.000185	0.000691	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—VEGFA—amyotrophic lateral sclerosis	0.000183	0.000682	CbGpPWpGaD
Sirolimus—CYP3A5—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000183	0.000682	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	0.000182	0.00068	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000182	0.000679	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000181	0.000674	CbGpPWpGaD
Sirolimus—MTOR—Disease—CHMP2B—amyotrophic lateral sclerosis	0.00018	0.000671	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	0.00018	0.000671	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00018	0.00067	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000175	0.000653	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000174	0.000647	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000174	0.000646	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	0.000173	0.000645	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000171	0.000638	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—ERBB4—amyotrophic lateral sclerosis	0.00017	0.000635	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000169	0.000631	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000167	0.000623	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000164	0.000613	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000164	0.000611	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	0.000163	0.000609	CbGpPWpGaD
Sirolimus—MTOR—Disease—PLB1—amyotrophic lateral sclerosis	0.000163	0.000607	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000163	0.000606	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD40LG—amyotrophic lateral sclerosis	0.00016	0.000597	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000157	0.000586	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	0.000156	0.000582	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000156	0.00058	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—DAO—amyotrophic lateral sclerosis	0.000155	0.000577	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000154	0.000573	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000154	0.000573	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—CASP3—amyotrophic lateral sclerosis	0.00015	0.000557	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—amyotrophic lateral sclerosis	0.000149	0.000554	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.000148	0.000551	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000147	0.000549	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000147	0.000548	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	0.000147	0.000547	CbGpPWpGaD
Sirolimus—MTOR—Disease—VCP—amyotrophic lateral sclerosis	0.000145	0.000541	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000145	0.000539	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000144	0.000537	CbGpPWpGaD
Sirolimus—MTOR—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000144	0.000536	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—DAO—amyotrophic lateral sclerosis	0.000142	0.00053	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000142	0.00053	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000142	0.00053	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—C3—amyotrophic lateral sclerosis	0.000142	0.000527	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—MMP9—amyotrophic lateral sclerosis	0.000141	0.000527	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.000141	0.000525	CbGpPWpGaD
Sirolimus—FGF2—Disease—CST3—amyotrophic lateral sclerosis	0.000141	0.000523	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	0.00014	0.000523	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000137	0.000511	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	0.000135	0.000504	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000135	0.000503	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—C3—amyotrophic lateral sclerosis	0.000135	0.000503	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CASP9—amyotrophic lateral sclerosis	0.000135	0.000502	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000133	0.000495	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00013	0.000484	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—C3—amyotrophic lateral sclerosis	0.00013	0.000483	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000129	0.000479	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	0.000125	0.000467	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000124	0.000463	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000124	0.000462	CbGpPWpGaD
Sirolimus—FGF2—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.000124	0.000462	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	0.000123	0.000458	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000121	0.00045	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000121	0.00045	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000118	0.000441	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000118	0.000439	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000117	0.000437	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000117	0.000434	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ATF1—amyotrophic lateral sclerosis	0.000116	0.000433	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	0.000116	0.000432	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—ERBB4—amyotrophic lateral sclerosis	0.000115	0.00043	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000114	0.000425	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000114	0.000423	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000112	0.000417	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000111	0.000415	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CASP9—amyotrophic lateral sclerosis	0.000111	0.000412	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.00011	0.00041	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	0.000109	0.000406	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSR—amyotrophic lateral sclerosis	0.000108	0.000404	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000108	0.000401	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000107	0.0004	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000107	0.0004	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000107	0.0004	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	0.000106	0.000397	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000106	0.000394	CbGpPWpGaD
Sirolimus—MTOR—Disease—CST3—amyotrophic lateral sclerosis	0.000104	0.000388	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	0.000104	0.000388	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000104	0.000386	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	0.000103	0.000383	CbGpPWpGaD
Sirolimus—FGF2—Disease—CASP9—amyotrophic lateral sclerosis	0.000102	0.000381	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000102	0.000379	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—C3—amyotrophic lateral sclerosis	0.0001	0.000374	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSR—amyotrophic lateral sclerosis	9.94e-05	0.00037	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.91e-05	0.000369	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	9.87e-05	0.000368	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	9.85e-05	0.000367	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	9.81e-05	0.000365	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—C3—amyotrophic lateral sclerosis	9.63e-05	0.000359	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	9.51e-05	0.000354	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	9.51e-05	0.000354	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ERBB4—amyotrophic lateral sclerosis	9.47e-05	0.000353	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.44e-05	0.000352	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—VEGFA—amyotrophic lateral sclerosis	9.42e-05	0.000351	CbGpPWpGaD
Sirolimus—MTOR—Immune System—SQSTM1—amyotrophic lateral sclerosis	9.19e-05	0.000342	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.15e-05	0.000341	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.12e-05	0.00034	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—APOE—amyotrophic lateral sclerosis	8.93e-05	0.000333	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD40LG—amyotrophic lateral sclerosis	8.9e-05	0.000332	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CHAT—amyotrophic lateral sclerosis	8.9e-05	0.000331	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	8.75e-05	0.000326	CbGpPWpGaD
Sirolimus—FGF2—Disease—ERBB4—amyotrophic lateral sclerosis	8.74e-05	0.000326	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	8.65e-05	0.000322	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	8.62e-05	0.000321	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ATF1—amyotrophic lateral sclerosis	8.62e-05	0.000321	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	8.57e-05	0.000319	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MMP9—amyotrophic lateral sclerosis	8.56e-05	0.000319	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.52e-05	0.000317	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	8.51e-05	0.000317	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	8.48e-05	0.000316	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CASP9—amyotrophic lateral sclerosis	8.21e-05	0.000306	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CHAT—amyotrophic lateral sclerosis	8.17e-05	0.000304	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	8.12e-05	0.000302	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.08e-05	0.000301	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	8.04e-05	0.0003	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	8.01e-05	0.000298	CbGpPWpGaD
Sirolimus—FGF2—Immune System—C3—amyotrophic lateral sclerosis	7.87e-05	0.000293	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	7.79e-05	0.00029	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	7.75e-05	0.000289	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	7.69e-05	0.000286	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.6e-05	0.000283	CbGpPWpGaD
Sirolimus—MTOR—Disease—CASP9—amyotrophic lateral sclerosis	7.58e-05	0.000282	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.51e-05	0.00028	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	7.19e-05	0.000268	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7.15e-05	0.000267	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—amyotrophic lateral sclerosis	7.12e-05	0.000265	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.04e-05	0.000262	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB4—amyotrophic lateral sclerosis	7.03e-05	0.000262	CbGpPWpGaD
Sirolimus—FGF2—Disease—APOE—amyotrophic lateral sclerosis	6.76e-05	0.000252	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.71e-05	0.00025	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	6.67e-05	0.000248	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	6.61e-05	0.000246	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	6.61e-05	0.000246	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD40LG—amyotrophic lateral sclerosis	6.61e-05	0.000246	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB4—amyotrophic lateral sclerosis	6.49e-05	0.000242	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.25e-05	0.000233	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	6.19e-05	0.000231	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6.12e-05	0.000228	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTGS2—amyotrophic lateral sclerosis	6.12e-05	0.000228	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	6.04e-05	0.000225	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	5.94e-05	0.000221	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	5.9e-05	0.00022	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	5.88e-05	0.000219	CbGpPWpGaD
Sirolimus—MTOR—Immune System—C3—amyotrophic lateral sclerosis	5.84e-05	0.000218	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.76e-05	0.000214	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.62e-05	0.000209	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	5.57e-05	0.000208	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	5.56e-05	0.000207	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	5.42e-05	0.000202	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.42e-05	0.000202	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	5.31e-05	0.000198	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	5.28e-05	0.000197	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	5.25e-05	0.000196	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.16e-05	0.000192	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.12e-05	0.000191	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.09e-05	0.00019	CbGpPWpGaD
Sirolimus—MTOR—Disease—APOE—amyotrophic lateral sclerosis	5.02e-05	0.000187	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.78e-05	0.000178	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	4.78e-05	0.000178	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.74e-05	0.000176	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—amyotrophic lateral sclerosis	4.64e-05	0.000173	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.6e-05	0.000171	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.54e-05	0.000169	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	4.45e-05	0.000166	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.39e-05	0.000164	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.39e-05	0.000163	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.27e-05	0.000159	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.03e-05	0.00015	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.98e-05	0.000148	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.97e-05	0.000148	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.91e-05	0.000146	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.78e-05	0.000141	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.76e-05	0.00014	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	3.62e-05	0.000135	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—APOE—amyotrophic lateral sclerosis	3.62e-05	0.000135	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.52e-05	0.000131	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.48e-05	0.000129	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—amyotrophic lateral sclerosis	3.44e-05	0.000128	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.37e-05	0.000126	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	3.34e-05	0.000124	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—APOE—amyotrophic lateral sclerosis	3.32e-05	0.000124	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.17e-05	0.000118	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.01e-05	0.000112	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.92e-05	0.000109	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.9e-05	0.000108	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.85e-05	0.000106	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	2.74e-05	0.000102	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.56e-05	9.52e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.55e-05	9.5e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.48e-05	9.23e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	2.4e-05	8.94e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.39e-05	8.92e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.27e-05	8.47e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.24e-05	8.33e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.2e-05	8.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.11e-05	7.87e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.93e-05	7.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.9e-05	7.07e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	1.81e-05	6.74e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.64e-05	6.12e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.47e-05	5.49e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.43e-05	5.34e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.36e-05	5.05e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.24e-05	4.62e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.12e-05	4.15e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.64e-06	2.85e-05	CbGpPWpGaD
